Tumor Necrosis Factor Alpha and Neutrophil Lymphocytic Ratio in Non-Alcoholic Fatty Liver Diseases

Abstract

Abstract Background Non-alcoholic fatty liver disease (NAFLD) is one of the most common causes of chronic liver disease worldwide. Some patients with NAFLD progress to liver fibrosis, cirrhosis and hepatocellular carcinoma. Therefore, the precise diagnosis and staging of NAFLD patients is clinically important. Objective To investigate the relationship between tumor necrosis factor alpha level and neutrophil lymphocytic ratio with the development of nonalcoholic fatty liver disease (NAFLD) from simple steatosis stage to liver fibrosis. Patients and Methods In the present study, we assess the value of TNF-α and N/L ratio as a noninvasive biomarker for diagnosis of NAFLD and NASH. All patients enrolled in the study fulfilled the mentioned inclusion criteria. They all were subjected to history taking and clinical examination upon admission. An informed consent was taken from all patients before enrollment in the study. Privacy of the participants and confidently of the data is preserved. Any unexpected risk appeared during the course of the study were being cleared to the participants and ethical committee on time. Results Patients with NASH had lower platelet count, higher INR, higher total bilirubin, higher serum AST, and higher serum ALT, lower serum albumin than normal controls and NAFLD patients. Likewise, patients with NAFLD had lower platelet count, higher INR, higher total bilirubin, higher serum AST, and higher serum ALT, lower serum albumin than normal controls. Patients with NASH had higher serum FBS and serum cholesterol, higher NAFLD score than normal controls and NAFLD patients. Likewise, patients with NAFLD had higher serum FBS and serum cholesterol, higher NAFLD score than normal controls. Patients with NASH had significantly higher values of TNF-α and N/L ratio. Conclusion Nonalcoholic fatty liver disease (NAFLD) increasing in parallel with obesity, insulin resistance, hypertension and dyslipidemia and is now regarded as the liver manifestation of the metabolic syndrome. Serum levels of TNF-α and N/L ratio may represent novel, noninvasive biomarkers of diagnosis and histological disease severity in patients with NAFLD and NASH. And can be a useful predictive marker of liver fibrosis.